Bank of India Mutual FundEquity Schemes - Mid Cap Fund1.2 years
The scheme is to generate long-term capital appreciation by investing predominantly in equity and equity related instruments of mid cap companies. However, there is no assurance that the investment objective of the Scheme will be achieved.
Buying brief
Evidence on this desk, framed as a purchase checklist - not SEBI-registered advice.
As of 29 Oct 2026
Stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
In three lines
Fits if · Peak-to-trough drawdown has stayed shallower than 15%.
Prefer peers if · Prefer BANDHAN MID CAP FUND if you want a same-category peer with stronger evidence.
Buy checklist
History depth
Fail
1.2 years - thin for judging consistency.
Engine status
Watch
Recent evidence is mixed. Compare peers before increasing exposure.
Expense ratio
Pass
1.37% TER (Direct). Lower cost compounds on long SIPs.
Drawdown vs peers
Pass
Peak-to-trough -12.5%. Ask whether you can hold through a similar fall.
Vs category
n/a
Category relative read still thin.
Manager tenure
Watch
Alok Singh · 1.3 years on the scheme.
Exit load
n/a
No exit-load summary on file.
Tax / wrapper
Pass
Direct Growth, no ELSS lock flagged. Equity LTCG rules still apply after one year - not tax advice.
Portfolio concentration
Pass
Top 10 holdings ≈ 39.2% of the portfolio.
Same-category peers are preloaded into compare when available.
Behaviour and wrappers - the usual India MF failure modes - not a buy instruction.
Drawdown rehearsal
This scheme’s worst fall on file is about 12%. Before you SIP, ask whether you would keep contributing through a similar drop - pausing on fear is the usual India MF failure mode.
SIP discipline
Monitor is recent mixed evidence - keep the SIP unless the buying brief says prefer peers, then swap with intent.
NAV
Path not in current snapshots
n/a
Trailing CAGR and simulated monthly SIP XIRR from daily NAV. Category comparison uses the median of comparable share classes in the peer set.
Trailing CAGR
Point-to-point, calendar-day annualized
SIP XIRR
Equal monthly instalments to latest NAV
Date-aligned against NIFTY MIDCAP 150 TRI. Capture ratios use common month-end observations through 30 Oct 2026.
Peak to trough from a running NAV high, with the path and recovery episodes.
Drawdown
Path not in current snapshots
n/a
3 Nov 2025 – 29 Apr 2026
Trough 23 Mar 2026 · recovered in 37 days
-12.5%
31 Aug 2026 – open
Trough 23 Oct 2026 · not recovered
-10.4%
26 May 2026 – 18 Jun 2026
Trough 11 Jun 2026 · recovered in 7 days
-5.0%
22 Jun 2026 – 5 Aug 2026
Trough 8 Jul 2026 · recovered in 28 days
-3.4%
0–100 reads of named metrics. The mean is unweighted and only uses dimensions with data.
Returns
20
Vs category
44
Consistency
0
Risk-adjusted
11
Drawdown
69
Mean
29
Quantitative engine reasons behind the buying stance. An explanation can only restate what is already here.
Buying stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
Why this status
Supporting reads
30 Sept 2026 · 58 holdings · top 10 are 39.2%.
Aurobindo Pharma Ltd
Healthcare
5.7%
Net Receivables
Unspecified
5.1%
Multi Commodity Exchange Of India Ltd
Financial
5.0%
Abbott India Ltd
Healthcare
4.8%
One 97 Communications Ltd
Industrials
3.5%
Same-category peers with enough history to inspect beside this fund - including tradeoffs.
Bandhan Mutual Fund
Caveat: Higher volatility · Deeper drawdown
Helios Mutual Fund
Caveat: Higher volatility · Deeper drawdown
HSBC Mutual Fund
Caveat: Higher volatility · Deeper drawdown
ICICI Prudential Mutual Fund
Caveat: Higher volatility · Deeper drawdown
Invesco Mutual Fund
Caveat: Higher volatility · Deeper drawdown
Bank of India Mutual FundEquity Schemes - Mid Cap Fund1.2 years
The scheme is to generate long-term capital appreciation by investing predominantly in equity and equity related instruments of mid cap companies. However, there is no assurance that the investment objective of the Scheme will be achieved.
Buying brief
Evidence on this desk, framed as a purchase checklist - not SEBI-registered advice.
As of 29 Oct 2026
Stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
In three lines
Fits if · Peak-to-trough drawdown has stayed shallower than 15%.
Prefer peers if · Prefer BANDHAN MID CAP FUND if you want a same-category peer with stronger evidence.
Buy checklist
History depth
Fail
1.2 years - thin for judging consistency.
Engine status
Watch
Recent evidence is mixed. Compare peers before increasing exposure.
Expense ratio
Pass
1.37% TER (Direct). Lower cost compounds on long SIPs.
Drawdown vs peers
Pass
Peak-to-trough -12.5%. Ask whether you can hold through a similar fall.
Vs category
n/a
Category relative read still thin.
Manager tenure
Watch
Alok Singh · 1.3 years on the scheme.
Exit load
n/a
No exit-load summary on file.
Tax / wrapper
Pass
Direct Growth, no ELSS lock flagged. Equity LTCG rules still apply after one year - not tax advice.
Portfolio concentration
Pass
Top 10 holdings ≈ 39.2% of the portfolio.
Same-category peers are preloaded into compare when available.
Behaviour and wrappers - the usual India MF failure modes - not a buy instruction.
Drawdown rehearsal
This scheme’s worst fall on file is about 12%. Before you SIP, ask whether you would keep contributing through a similar drop - pausing on fear is the usual India MF failure mode.
SIP discipline
Monitor is recent mixed evidence - keep the SIP unless the buying brief says prefer peers, then swap with intent.
NAV
29 Oct 2026 · -1.0% over 1Y
10.07
Trailing CAGR and simulated monthly SIP XIRR from daily NAV. Category comparison uses the median of comparable share classes in the peer set.
Trailing CAGR
Point-to-point, calendar-day annualized
SIP XIRR
Equal monthly instalments to latest NAV
Date-aligned against NIFTY MIDCAP 150 TRI. Capture ratios use common month-end observations through 30 Oct 2026.
Peak to trough from a running NAV high, with the path and recovery episodes.
Drawdown
29 Oct 2026
-6.9%
3 Nov 2025 – 29 Apr 2026
Trough 23 Mar 2026 · recovered in 37 days
-12.5%
31 Aug 2026 – open
Trough 23 Oct 2026 · not recovered
-10.4%
26 May 2026 – 18 Jun 2026
Trough 11 Jun 2026 · recovered in 7 days
-5.0%
22 Jun 2026 – 5 Aug 2026
Trough 8 Jul 2026 · recovered in 28 days
-3.4%
0–100 reads of named metrics. The mean is unweighted and only uses dimensions with data.
Returns
20
Vs category
44
Consistency
0
Risk-adjusted
11
Drawdown
69
Mean
29
Quantitative engine reasons behind the buying stance. An explanation can only restate what is already here.
Buying stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
Why this status
Supporting reads
30 Sept 2026 · 58 holdings · top 10 are 39.2%.
Aurobindo Pharma Ltd
Healthcare
5.7%
Net Receivables
Unspecified
5.1%
Multi Commodity Exchange Of India Ltd
Financial
5.0%
Abbott India Ltd
Healthcare
4.8%
One 97 Communications Ltd
Industrials
3.5%